Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.
about
Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migrationNew insights into mechanisms of resistance to microtubule inhibitorsA ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferationMegakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division.Class V β-tubulin alters dynamic instability and stimulates microtubule detachment from centrosomes.Regulation of mitosis and taxane response by Daxx and Rassf1.Epothilone D prevents binge methamphetamine-mediated loss of striatal dopaminergic markers.Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents.Microtubules and their role in cellular stress in cancerDocetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transitionInhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin.βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancerRationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis.Clinical trial designs for testing biomarker-based personalized therapies.Prognostic biomarkers for HNSCC using quantitative real-time PCR and microarray analysis: β-tubulin isotypes and the p53 interactome.Mitotic centromere-associated kinesin (MCAK) mediates paclitaxel resistanceMechanisms of resistance to cabazitaxel.Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials GroupAdvancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane.Induction of neural differentiation in rat C6 glioma cells with taxolAltered TUBB3 expression contributes to the epothilone response of mitotic cells.Synthesis of N(4)-(substituted phenyl)-N(4)-alkyl/desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines and identification of new microtubule disrupting compounds that are effective against multidrug resistant cells.Anticancer drugs from nature--natural products as a unique source of new microtubule-stabilizing agents.Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.Molecular basis for class V beta-tubulin effects on microtubule assembly and paclitaxel resistance.The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancerThe taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.New microtubule-inhibiting anticancer agents.Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.Peloruside, laulimalide, and noscapine interactions with beta-tubulin.Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?Tubulin: an example of targeted chemotherapy.An update on the current pharmacotherapy for endometrial cancer.The Elephant in the Room: The Role of Microtubules in Cancer.An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy ResistanceModulation of septin and molecular motor recruitment in the microtubule environment of the Taxol-resistant human breast cancer cell line MDA-MB-231.Regulation of β-tubulin isotypes by micro-RNA 100 in MCF7 breast cancer cells.
P2860
Q24617268-5943FEAF-24C2-4600-8726-908469900B97Q24633853-46D10E16-7D14-429F-84DD-3ABA1588B53AQ28512163-E2CE3461-E2F3-4E0F-9EB1-F8DDFA779007Q30428045-592132EC-AAE5-4E48-B1C5-28B364E1DB8AQ30431870-3776C874-09C8-4574-8C1B-C3613FB7A7D6Q30574064-BD5FE391-6B01-4F8C-A649-9FF8CDA651B1Q33583474-D253E760-75DA-4A2F-ABF2-63937E9AA4DCQ33630855-5BBBE1AD-B901-4AA5-A151-F224AEC492ABQ33770927-4FCD9FEA-F380-46D9-BD7D-302205586CC1Q33819310-24C25E11-82FF-40F4-94B8-8F011E2915F3Q33829740-E0BABFD6-D3AE-4455-8589-BC6D218BC38DQ33866286-5C86B8A5-A064-4F47-BF7C-84FDB00AA2D3Q34353248-6AAD2125-B4D3-4F86-8561-654030F3671EQ34360044-03043F14-4374-42C4-B11D-702BF85FE2D4Q34977663-DCEEB085-FB46-45D5-AFBB-ED0F39A43C40Q35199954-16B3565D-66FA-4604-B8E2-DF06A2BAF908Q35379041-01B300E6-A64E-4FB5-8BCB-9F0D879E0FCDQ35661531-8C13CF94-2367-445F-A81D-F9A3B64B6C24Q35800455-75F0E124-F3BD-402A-B2D1-A689C754A783Q35975007-9E829F31-10A6-40F0-B4A5-608546FE4743Q36244183-AC847DB1-A95D-46B9-927C-6DAE4F6AC741Q36341381-06FE4ED7-BCB2-4EFD-BA95-5BBA69AD57BBQ36557893-179F1170-875D-4503-B325-C34F4335F14DQ36610307-9B312FA9-175D-42F7-A478-62766FD3E6FDQ36772390-27F916FF-1E83-4253-94EF-04CA73C12329Q36980135-1FD31038-7DD8-432F-9200-880819FC8BE1Q37038455-943DE83E-2060-41D9-A87C-51B6DB1EA6A0Q37176441-D1CB59FB-D2F5-4D28-92BF-092F50A37980Q37194315-C64ADDAF-D456-4B14-AD46-EB191326460CQ37306809-69B806B1-8B76-4403-AB5A-C87FB84ACCA4Q37689138-DD154685-219C-45F1-8CAB-D0D1FB025D54Q37699264-821B9D67-9575-445A-910E-37CC5C4408CBQ38021666-546B1094-716D-4D92-AC1A-1B40E5EB0A9CQ38069185-AF73E7E4-4426-4C4E-B7A0-8CCFC9CBF5CBQ38086872-84BD8A73-70CF-43F2-9970-AFE73A7F6785Q38656675-6CD78152-81C9-4207-A15B-64FD32BC6E2DQ38672574-52FC577E-64A3-43C2-9BC2-CD5DAC51934AQ39414846-FBE1604E-7C2E-4D55-AA68-4CDF1A6F6C88Q39506195-6551D023-4B4D-4822-A71D-A390F66FBEAAQ39531807-B11B9A68-A56A-4AF8-8B3F-E9211436E0B7
P2860
Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Expression of class III beta-t ...... fers resistance to paclitaxel.
@ast
Expression of class III beta-t ...... fers resistance to paclitaxel.
@en
type
label
Expression of class III beta-t ...... fers resistance to paclitaxel.
@ast
Expression of class III beta-t ...... fers resistance to paclitaxel.
@en
prefLabel
Expression of class III beta-t ...... fers resistance to paclitaxel.
@ast
Expression of class III beta-t ...... fers resistance to paclitaxel.
@en
P2093
P356
P1433
P1476
Expression of class III beta-t ...... fers resistance to paclitaxel.
@en
P2093
Changqing Zeng
Fernando Cabral
Hailing Yang
Malathi Hari
Martin Canizales
P356
10.1002/CM.10132
P577
2003-09-01T00:00:00Z